Compare Enovix Corporation (ENVX) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Hinge Health Inc. Class A Common Stock — how do they compare? Enovix Corporation trades at $2.38 (market cap $550.82M), while Hinge Health Inc. Class A Common Stock trades at $103.96 (market cap $8.48B). The key difference: Hinge Health Inc. Class A Common Stock is far larger — about 15.4× Enovix Corporation's market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| ENVX | HNGE | |
|---|---|---|
Market Cap | $550.82M | $8.48B |
Volume | 5,977,872 | 879,799 |
Sector | Industrials | Health |
52-Week High | $13.19 | $105.14 |
52-Week Low | $2.44 | $31.17 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $612.51M | $8.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.51, down 3.09% on the day, reflecting bearish technical signals and negative profitability. The company reported a net loss of -$156.74M in 2025, with revenue of $31.82M, while recent quarterly EPS has consistently beaten expectations. Key developments include a CEO transition in August 2026 and expansion of drone battery capacity in South Korea.
Despite deep losses and cash burn, analyst consensus remains bullish with a $9.60 price target, citing potential in defense and smartphone battery markets. Risks include high cash burn, leadership changes, and competitive pressures. The stock's outlook hinges on successful commercialization and margin improvement.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
